FindTrial
Sign In

Construction and application of standardized clinical pathway for the complex decongestive therapy(CDT) of breast cancer-related lymphedema after breast cancer surgery

Construction and application of standardized clinical pathway for the complex decongestive therapy(CDT) of breast cancer-related lymphedema after breast cancer surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025534
Enrollment
Unknown
Registered
2019-08-31
Start date
2019-08-28
Completion date
Unknown
Last updated
2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer-Related Lymphedema

Interventions

Experimental group:Complex Decongestive Therapy
control group:conventional therapy

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed breast cancer and lymphedema after axillary dissection (and/or) radiotherapy/chemotherapy; 2. Prective survival time is more than 6 months; 3. Patient who has signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Any kind of acute infection; 2. Cardiogenic edema; 3. Limb edema is caused by metastasis or recurrence of breast cancer; 4. Renal failure; 5. Acute deep venous thrombosis; 6. Artery disease; 7. Random blood pressure >=140/90mmhg; 8. Stroke; 9. Fasting plasma glucose>=7.0mmol/L or blood glucose>=11.1mmol/L 2 hours after meal; 10. Bronchial croup.

Design outcomes

Primary

MeasureTime frame
Circumference of affected limbs;—

Countries

China

Contacts

Public ContactWu Shaoyong

West China Hospital, Sichuan University

wusy6@163.com+86 18980441696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026